Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013:2013:194389.
doi: 10.1155/2013/194389. Epub 2013 Aug 19.

Evaluation of extended interval dosing aminoglycosides in the morbidly obese population

Ashley L Ross  1 , Jennifer L Tharp, Gerald R Hobbs, Richard McKnight, Aaron Cumpston
Affiliations

Evaluation of extended interval dosing aminoglycosides in the morbidly obese population

Ashley L Ross et al. Adv Pharmacol Sci. 2013.

Abstract

Aminoglycoside dosing has been studied in the obese population, typically recommending an adjusted weight utilizing a 40% dosing weight correction factor (IBW + 0.4 × (TBW-IBW)). These studies included limited numbers of morbidly obese patients and were not done in the era of extended interval aminoglycoside dosing. Here, we report a retrospective evaluation of morbidly obese patients receiving gentamicin or tobramycin at our hospital. The objective of this study was to evaluate the accuracy of the commonly recommended adjusted weight for weight-based dosing. There were 31 morbidly obese patients who received gentamicin or tobramycin 5-7 mg/kg every 24 hours using a 40% dosing weight correction factor. Our institution utilizes 16-hour postdose concentrations to monitor extended interval aminoglycosides. Twenty-two of the 31 patients (71%) achieved an appropriate serum drug concentration. Four patients (13%) were found to be supratherapeutic and 5 patients (16%) subtherapeutic. The only variable that correlated with supratherapeutic levels was older age (P = 0.0378). Our study helps to validate the current dosing weight correction factor (40%) in the morbidly obese population. We recommend caution when dosing aminoglycosides in morbidly obese patients who are of older age.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Aminoglycoside serum concentrations.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. The World Health Organization. Obesity Fact Sheet. March 2013, http://www.who.int/topics/obesity/en/
    1. Centers for Disease Control and Prevention. Adult Obesity Facts. March 2013, http://www.cdc.gov/obesity/data/adult.html.
    1. Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients: insights from the society of infectious diseases pharmacists. Pharmacotherapy. 2007;27(8):1081–1091. - PubMed
    1. Newman D, Scheetz MH, Adeyemi OA, et al. Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual. Annals of Pharmacotherapy. 2007;41(10):1734–1739. - PubMed
    1. Lee JB, Winstead S, Cook AM. Pharmacokinetic alterations in obesity. Orthopedics. 2006;29(11):984–988. - PubMed

LinkOut - more resources